No connection

Search Results

INCR

BEARISH
$0.76 Live
InterCure Ltd. · NASDAQ
$0.68 52W Range $1.77

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 12, 2026
Market cap
$41.72M
P/E
N/A
ROE
-16.7%
Profit margin
-29.2%
Debt/Equity
0.41
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
InterCure Ltd. exhibits severe financial distress as evidenced by a weak Piotroski F-Score of 2/9, indicating poor operational efficiency and financial health. Despite a very low Price-to-Book ratio of 0.10, the company is trapped in a catastrophic long-term price decline, losing over 91% of its value over five years. Negative profit margins and crashing EPS growth suggest that the low valuation is a value trap rather than a bargain. The lack of analyst coverage and a 0/100 technical trend further reinforce a bearish outlook.

Key Strengths

Low Debt-to-Equity ratio (0.41) suggests manageable leverage
Current Ratio of 1.85 indicates adequate short-term liquidity
Positive Gross Margin (16.71%) shows core product viability
Quick Ratio above 1.0 indicates ability to cover immediate liabilities
Extremely low Price-to-Book ratio (0.10) provides a theoretical floor

Key Risks

Severe operational weakness indicated by Piotroski F-Score of 2/9
Negative profit margins (-29.17%) and negative ROE (-16.68%)
Catastrophic price performance (-91.7% over 5 years)
Stagnant revenue growth (3.40% YoY) failing to keep pace with inflation
Significant earnings volatility and recent EPS collapse (-66.7% YoY)
AI Fair Value Estimate
Based on comprehensive analysis
$0.65
-14.8% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
18
Weak
Value
40
Future
20
Past
10
Health
20
Dividend
0
AI Verdict
High Risk / Value Trap
Key drivers: Piotroski F-Score of 2/9, 5-year price decay of 91.7%, Negative net profitability, Bearish technical trend
Confidence
90%
Value
40/100

Trades at a massive discount to book value, but earnings quality is too poor to justify a value play.

Positives
  • P/B ratio of 0.10 is exceptionally low
Watchpoints
  • No Graham Number available
  • Negative earnings make P/E metrics irrelevant
Future
20/100

Growth metrics are insufficient to reverse the current downward trajectory.

Positives
  • Marginal revenue growth (3.4%)
Watchpoints
  • EPS growth is crashing (-72.7% Q/Q)
  • Technical trend is 0/100 (Bearish)
Past
10/100

Historical performance is overwhelmingly negative across 1, 3, and 5-year horizons.

Positives
No standout positives identified.
Watchpoints
  • Consistent multi-year price collapse
  • Poor earnings track record
Health
20/100

Balance sheet liquidity is the only saving grace, but operational health is failing.

Positives
  • Low Debt/Equity
  • Healthy Current Ratio
Watchpoints
  • Piotroski F-Score 2/9 indicates fundamental weakness
Dividend
0/100

Company is not returning capital to shareholders.

Positives
No standout positives identified.
Watchpoints
  • No dividend payments
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$0.76

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for INCR and closest competitors.

Updated 2026-04-10
INC
InterCure Ltd.
Primary
5Y
-91.7%
3Y
-67.4%
1Y
-37.5%
6M
-52.3%
1M
-4.7%
1W
+0.4%
APL
Apollomics, Inc.
Peer
5Y
-98.0%
3Y
-98.1%
1Y
+148.8%
6M
+191.4%
1M
-0.5%
1W
-0.8%
ARA
Accuray Incorporated
Peer
5Y
-93.2%
3Y
-87.0%
1Y
-78.7%
6M
-76.4%
1M
-27.4%
1W
-24.4%
BDM
Baird Medical Investment Holdings Limited
Peer
5Y
-89.3%
3Y
-90.0%
1Y
-87.4%
6M
-49.5%
1M
-26.9%
1W
-10.4%
ATR
Atara Biotherapeutics, Inc.
Peer
5Y
-98.9%
3Y
-95.6%
1Y
-24.7%
6M
-54.9%
1M
-70.3%
1W
+15.0%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-0.52
PEG Ratio
N/A
P/B Ratio
0.1
P/S Ratio
N/A
EV/Revenue
N/A
EV/EBITDA
N/A
Market Cap
$41.72M

Profitability

Profit margins and return metrics

Profit Margin -29.18%
Operating Margin N/A
Gross Margin 16.71%
ROE -16.68%
ROA -7.74%

Growth

Revenue and earnings growth rates

Revenue Growth +3.4%
Earnings Growth N/A
Q/Q Revenue Growth N/A
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.41
Low debt
Current Ratio
1.85
Good
Quick Ratio
1.08
Good
Cash/Share
$N/A

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2024

Total Assets
$0.8B
Liabilities
$0.4B
Equity
$0.4B
Debt/Equity
0.92x

Quarterly Earnings History

EPS performance vs analyst estimates

2023-08-31
$0.03
+105.1% surprise
2023-05-15
$N/A
-85.1% surprise
2023-03-30
$0.11
+115.3% surprise
2022-11-15
$0.04
-51.5% surprise

Healthcare Sector Comparison

Comparing INCR against 264 companies in the Healthcare sector (20 bullish, 87 neutral, 157 bearish)
Return on Equity (ROE)
-16.68%
This Stock
vs
-46.09%
Sector Avg
-63.8% (Below Avg)
Profit Margin
-29.18%
This Stock
vs
-19.58%
Sector Avg
+49.0% (Superior)
Debt to Equity
0.41
This Stock
vs
4.1
Sector Avg
-89.9% (Less Debt)
Revenue Growth
3.4%
This Stock
vs
88.16%
Sector Avg
-96.1% (Slower)
Current Ratio
1.85
This Stock
vs
3.58
Sector Avg
-48.2% (Weaker)

Similar Companies

Peer comparison within the same industry

Past News Coverage

Recent headlines mentioning INCR from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile